Belvedere Trading
NAGE

Belvedere Trading’s Niagen Bioscience NAGE Stock Holding History

Belvedere Trading’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-5,960
Closed -$35K – 661
2021
Q3 		$35K Sell
5,960
-11,856
-67% -$97.7K ﹤0.01% 433
2021
Q2 		$163K Sell
17,816
-26,297
-60% -$229K 0.01% 218
2021
Q1 		$412K Buy
+44,113
New +$350K 0.03% 105

Other funds holding NAGE

YRHAM
Yong Rong (HK) Asset Management Sheung Wan, Hong Kong $227M AUM 300.38% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Belvedere Trading's NAGE Position: Q4 2021 in Review

Belvedere Trading sold out of Niagen Bioscience (NAGE) in Q4 2021, closing a stake of 5,960 shares — an estimated $35K sold.

Belvedere Trading first reported a position in NAGE in Q1 2021 and held it in 3 quarters. The position peaked at $412K in Q1 2021. 83 funds tracked by Wall St. Rank hold NAGE as of Q4 2021.

  • Belvedere Trading reported no remaining Niagen Bioscience position as of Q4 2021 after selling out during the quarter.
  • Belvedere Trading sold 5,960 Niagen Bioscience shares in Q4 2021, an estimated $35K.
  • Belvedere Trading first reported a position in Niagen Bioscience in Q1 2021 and held it in 3 quarters.
  • Belvedere Trading's Niagen Bioscience position peaked at $412K in Q1 2021.
  • 83 funds tracked by Wall St. Rank held Niagen Bioscience as of Q4 2021.

Based on Belvedere Trading's 13F filing for Q4 2021, filed 25 Jan 2022.